Cytek Biosciences Inc - Asset Resilience Ratio

Latest as of March 2026: 43.77%

Cytek Biosciences Inc (CTKB) has an Asset Resilience Ratio of 43.77% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check CTKB PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$196.56 Million
Cash + Short-term Investments

Total Assets

$449.11 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how Cytek Biosciences Inc's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Cytek Biosciences Inc to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Cytek Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CTKB market cap.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $196.56 Million 43.77%
Total Liquid Assets $196.56 Million 43.77%

Asset Resilience Insights

  • Very High Liquidity: Cytek Biosciences Inc maintains exceptional liquid asset reserves at 43.77% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Cytek Biosciences Inc Industry Peers by Asset Resilience Ratio

Compare Cytek Biosciences Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Cochlear Ltd
AU:COH
Medical Devices 9.76%
Shenzhen New Industries Biomedical
SHE:300832
Medical Devices 9.95%
Jafron Biomedical Co Ltd
SHE:300529
Medical Devices 39.15%
HOB Biotech Group Corp Ltd
SHG:688656
Medical Devices 2.62%
Polynovo Ltd
AU:PNV
Medical Devices 0.04%
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
Medical Devices 10.88%
Dirui Industrial Co Ltd
SHE:300396
Medical Devices 6.89%
Emvision Medical Devices Ltd
AU:EMV
Medical Devices 0.06%

Annual Asset Resilience Ratio for Cytek Biosciences Inc (2021–2025)

The table below shows the annual Asset Resilience Ratio data for Cytek Biosciences Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 36.98% $170.68 Million $461.54 Million +1.11pp
2024-12-31 35.86% $179.15 Million $499.50 Million +16.63pp
2023-12-31 19.24% $95.11 Million $494.46 Million +10.66pp
2022-12-31 8.58% $44.55 Million $519.48 Million --
2021-12-31 0.00% $0.00 $463.31 Million --
pp = percentage points

About Cytek Biosciences Inc

NASDAQ:CTKB USA Medical Devices
Market Cap
$513.99 Million
Market Cap Rank
#12273 Global
#3010 in USA
Share Price
$3.98
Change (1 day)
-2.69%
52-Week Range
$2.95 - $5.88
All Time High
$27.93
About

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies usin… Read more